Allison Bratzel
Stock Analyst at Piper Sandler
(4.73)
# 143
Out of 4,984 analysts
41
Total ratings
75%
Success rate
19.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $750 → $820 | $752.32 | +9.00% | 14 | Aug 26, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $65 | $61.32 | +6.01% | 2 | Aug 22, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $82.28 | +36.12% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $5.79 | +279.97% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $12.36 | +166.99% | 1 | May 21, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $29.48 | +290.09% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $2.83 | +112.01% | 1 | Mar 14, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $6.07 | +328.69% | 1 | Feb 18, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $22.77 | -3.38% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $34.98 | -34.25% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $42 | $32.34 | +29.87% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $14.18 | +55.15% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.57 | +154.78% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $5.41 | +269.69% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $4.77 | +319.29% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $83.90 | +19.19% | 2 | Feb 8, 2023 |
argenx SE
Aug 26, 2025
Maintains: Overweight
Price Target: $750 → $820
Current: $752.32
Upside: +9.00%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $62 → $65
Current: $61.32
Upside: +6.01%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $82.28
Upside: +36.12%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $5.79
Upside: +279.97%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $12.36
Upside: +166.99%
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $29.48
Upside: +290.09%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $2.83
Upside: +112.01%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $6.07
Upside: +328.69%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $22.77
Upside: -3.38%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $34.98
Upside: -34.25%
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $32.34
Upside: +29.87%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $14.18
Upside: +55.15%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.57
Upside: +154.78%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.41
Upside: +269.69%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $4.77
Upside: +319.29%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $83.90
Upside: +19.19%